Literature DB >> 25903636

Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome.

S S C Rao1, S Yu1, A Fedewa2.   

Abstract

BACKGROUND: Dietary fibre supplements have been advocated for the management of chronic constipation (CC) and irritable bowel syndrome (IBS). Recently, a fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP) restricted diet has been recommended for IBS. AIM: To systematically examine recent evidence for dietary interventions with fibre in CC and IBS and FODMAP-restricted diet in IBS, and provide recommendations.
METHODS: We searched PUBMED, MEDLINE, OVID and COCHRANE databases from 2004 to 2014. Published studies in adults with CC and IBS and constipation-predominant IBS (IBS-C) that compared fibre with placebo/alternative and FODMAP-restricted diet with alternative were included.
RESULTS: Of 550 potentially eligible clinical trials on fibre, 11 studies were found and of 23 potentially eligible studies on FODMAPs, six were found. A meta-analysis was not performed due to heterogeneity and methodological quality. Fibre was beneficial in 5/7 studies in CC and 3/3 studies in IBS-C. FODMAP-restricted diet improved overall IBS symptoms in 4/4 and IBS-C symptoms in 1/3 studies and three studies did not meet inclusion criteria. There were significant disparities in subject selection, interventions and outcome assessments in both fibre and FODMAPs studies.
CONCLUSIONS: Fibre supplementation is beneficial in mild to moderate CC and IBS-C, although larger, more rigorous and long-term RCTs are needed (Fair evidence-Level II, Grade B). Although the FODMAP-restricted diet may be effective in short-term management of selected patients with IBS (Fair evidence-Level II, Grade C) and IBS-C (Poor evidence-Level III, Grade C), more rigorous trials are needed to establish long-term efficacy and safety, particularly on colonic health and microbiome.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903636     DOI: 10.1111/apt.13167

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  74 in total

1.  Low FODMAP diet.

Authors:  Cian Hackett; Michael R Kolber
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

2.  Diagnostic Utility of Carbohydrate Breath Tests for SIBO, Fructose, and Lactose Intolerance.

Authors:  Mercedes Amieva-Balmori; Enrique Coss-Adame; Nikilesh S Rao; Brisa M Dávalos-Pantoja; Satish S C Rao
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

3.  An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome.

Authors:  Jane Muir
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-07

4.  Chronic constipation, more needs to be done.

Authors:  Kok-Ann Gwee
Journal:  Indian J Gastroenterol       Date:  2018-11

5.  A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?

Authors:  Ayesha Shah; Mark Morrison; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2018-09

6.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

7.  Questionnaire on Irritable Bowel Syndrome and Symptom Management Among Endurance Athletes Is Valid and Reliable.

Authors:  Lauren A Killian; Karen M Chapman-Novakofski; Soo-Yeun Lee
Journal:  Dig Dis Sci       Date:  2018-09-19       Impact factor: 3.199

8.  Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.

Authors:  A Patel; S Hasak; B Cassell; M A Ciorba; E E Vivio; M Kumar; C Prakash Gyawali; G S Sayuk
Journal:  Aliment Pharmacol Ther       Date:  2016-05-30       Impact factor: 8.171

Review 9.  Restriction of FODMAP in the management of bloating in irritable bowel syndrome.

Authors:  Wei Mon Wong
Journal:  Singapore Med J       Date:  2016-09       Impact factor: 1.858

Review 10.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.